Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study

Rogério A. Costa, Rodrigo Jorge, Daniela Calucci, Luiz A. Melo, José A. Cardillo, Ingrid Scott

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

PURPOSE: To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). METHODS: In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. RESULTS: The median age of the 7 patients was 65 years (range, 58-74 years), and the median duration of symptoms before injection was 7 months (range, 2.5-16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, ≈20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 μm and 17.1 mm, respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 μm and 9.0 mm, respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. CONCLUSIONS: Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalRetina
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Retinal Vein
Retinal Vein Occlusion
Visual Acuity
Macular Edema
Intravitreal Injections
Fluorescein
Injections
Optical Coherence Tomography
Fluorescein Angiography
Hyperemia
Diabetic Retinopathy
Bevacizumab
Coloring Agents
Hemorrhage
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Costa, Rogério A. ; Jorge, Rodrigo ; Calucci, Daniela ; Melo, Luiz A. ; Cardillo, José A. ; Scott, Ingrid. / Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions : IBeVO study. In: Retina. 2007 ; Vol. 27, No. 2. pp. 141-149.
@article{d032b1c6e4424d5eadb359954627ff29,
title = "Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study",
abstract = "PURPOSE: To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). METHODS: In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. RESULTS: The median age of the 7 patients was 65 years (range, 58-74 years), and the median duration of symptoms before injection was 7 months (range, 2.5-16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, ≈20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 μm and 17.1 mm, respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 μm and 9.0 mm, respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. CONCLUSIONS: Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema.",
author = "Costa, {Rog{\'e}rio A.} and Rodrigo Jorge and Daniela Calucci and Melo, {Luiz A.} and Cardillo, {Jos{\'e} A.} and Ingrid Scott",
year = "2007",
month = "2",
day = "1",
doi = "10.1097/IAE.0b013e31802eff83",
language = "English (US)",
volume = "27",
pages = "141--149",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions : IBeVO study. / Costa, Rogério A.; Jorge, Rodrigo; Calucci, Daniela; Melo, Luiz A.; Cardillo, José A.; Scott, Ingrid.

In: Retina, Vol. 27, No. 2, 01.02.2007, p. 141-149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions

T2 - IBeVO study

AU - Costa, Rogério A.

AU - Jorge, Rodrigo

AU - Calucci, Daniela

AU - Melo, Luiz A.

AU - Cardillo, José A.

AU - Scott, Ingrid

PY - 2007/2/1

Y1 - 2007/2/1

N2 - PURPOSE: To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). METHODS: In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. RESULTS: The median age of the 7 patients was 65 years (range, 58-74 years), and the median duration of symptoms before injection was 7 months (range, 2.5-16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, ≈20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 μm and 17.1 mm, respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 μm and 9.0 mm, respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. CONCLUSIONS: Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema.

AB - PURPOSE: To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). METHODS: In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. RESULTS: The median age of the 7 patients was 65 years (range, 58-74 years), and the median duration of symptoms before injection was 7 months (range, 2.5-16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, ≈20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 μm and 17.1 mm, respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 μm and 9.0 mm, respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. CONCLUSIONS: Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema.

UR - http://www.scopus.com/inward/record.url?scp=33846945424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846945424&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31802eff83

DO - 10.1097/IAE.0b013e31802eff83

M3 - Article

C2 - 17290194

AN - SCOPUS:33846945424

VL - 27

SP - 141

EP - 149

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -